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Abstract
Background: Myelodysplastic syndromes (MDS) are a group of clonal hematological disorders characterized by 
ineffective hematopoiesis with morphological evidence of marrow cell dysplasia resulting in peripheral blood 
cytopenia. Microarray technology has permitted a refined high-throughput mapping of the transcriptional activity in 
the human genome. Non-coding RNAs (ncRNAs) transcribed from intronic regions of genes are involved in a number 
of processes related to post-transcriptional control of gene expression, and in the regulation of exon-skipping and 
intron retention. Characterization of ncRNAs in progenitor cells and stromal cells of MDS patients could be strategic for 
understanding gene expression regulation in this disease.
Methods: In this study, gene expression profiles of CD34+ cells of 4 patients with MDS of refractory anemia with ringed 
sideroblasts (RARS) subgroup and stromal cells of 3 patients with MDS-RARS were compared with healthy individuals 
using 44 k combined intron-exon oligoarrays, which included probes for exons of protein-coding genes, and for non-
coding RNAs transcribed from intronic regions in either the sense or antisense strands. Real-time RT-PCR was 
performed to confirm the expression levels of selected transcripts.
Results: In CD34+ cells of MDS-RARS patients, 216 genes were significantly differentially expressed (q-value ≤ 0.01) in 
comparison to healthy individuals, of which 65 (30%) were non-coding transcripts. In stromal cells of MDS-RARS, 12 
genes were significantly differentially expressed (q-value ≤ 0.05) in comparison to healthy individuals, of which 3 (25%) 
were non-coding transcripts.
Conclusions: These results demonstrated, for the first time, the differential ncRNA expression profile between MDS-
RARS and healthy individuals, in CD34+ cells and stromal cells, suggesting that ncRNAs may play an important role 
during the development of myelodysplastic syndromes.
Background
Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal hematological disorders characterized by
ineffective hematopoiesis with morphological evidence of
marrow cell dysplasia resulting in peripheral blood
cytopenia [1,2]. Low-risk MDS are characterized by pro-
found anemia and transfusion dependency, and a rela-
tively low risk of progression to acute myeloid leukemia.
Refractory anemia with ringed sideroblasts (RARS) is a
subtype of low-risk MDS in which an excess of iron accu-
mulates in the perinuclear mitochondria of ringed sidero-
blasts in the form of mitochondrial ferritin (MtF) [3-5].
However, the molecular genetic basis of RARS remains
unknown.
Gene expression profile of hematopoietic progenitor
cells of MDS patients demonstrates the involvement of
genes related to differentiation and proliferation of pro-
genitor cells [6-9]. Furthermore, there is increasing evi-
dence that, in certain hematological disorders, the
marrow microenvironment is abnormal, both in compo-
sition and function [10]. In MDS, the adherent layer of
bone marrow stroma is defective in supporting normal
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myelopoiesis in vitro, presenting a poor maintenance of
hematopoietic stem cells [11]. Alteration of stroma com-
ponents can be implicated in the modification of the
development and apoptosis of hematopoietic cells
[12,13].
The ENCODE project identified and characterized the
transcriptionally active regions in 1% of the human
genome, and described that the majority (63%) of tran-
scripts was of long non-coding RNAs (ncRNAs). These
transcripts resided outside GENCODE annotations, both
in intronic (40.9%) and intergenic (22.6%) regions [14].
Non-coding RNAs are known to be involved in different
biological processes such as cell survival and regulation of
cell-cycle progression [15], transcriptional or post-tran-
scriptional control of gene expression [16,17], genomic
imprinting [18] and biogenesis of mature RNAs through
changes in the intron-exon structure of host genes [19-
21]. In addition, introns have been shown to be sources of
short ncRNAs such as microRNAs [22] and small nucleo-
lar RNAs [23].
Microarray technology has permitted a refined high-
throughput mapping of the transcriptional activity in the
human genome [24], and has revealed different expres-
sion signatures of long intronic ncRNAs in prostate, liver
and kidney [25]. In addition, sets of long intronic ncRNAs
were found to be responsive to physiological stimuli such
as retinoic acid [26] or androgen hormone [27]. Long
ncRNAs change the interpretation of the functional basis
of many diseases [28,29]such as α-thalassemia [30],
Prader-Willi syndrome [31], and cancer [32-35]. Recently,
a myelopoiesis-associated regulatory intergenic non-cod-
ing RNA transcript has been described [36].
In the present study, expression profiles of CD34+ and
stromal cells of MDS-RARS patients and healthy individ-
uals were characterized with a 44 k combined intron-
exon oligoarray platform, allowing the identification of
protein-coding and intronic ncRNA expression signa-
tures in MDS-RARS patients.
Methods
Patients
Bone marrow (BM) samples were collected from 4
healthy subjects and 7 MDS patients, seen at the Hema-
tology and Hemotherapy Center, University of Campinas.
All patients were diagnosed as RARS according to the
French-American-British (FAB) classification and did not
present chromosomal abnormalities; they received no
growth factors or any further MDS treatment. Patients'
characteristics are shown in Table 1. All patients and
healthy subjects provided informed written consent and
the National Ethical Committee Board of School of Med-
ical Science - University of Campinas approved the study.
CD34+ cell and stromal cell selection
BM mononuclear cells were isolated by density-gradient
centrifugation through Ficoll-Paque Plus (GE Healthcare,
Uppsala, Sweden), labeled with CD34 MicroBeads, and
CD34+ cells were isolated using MACS magnetic cell sep-
aration columns (Miltenyi Biotec, Mönchengladbach,
Germany) according to the manufacturer's instructions.
The purity of CD34+ cells was at least 92% as determined
by fluorescence-activated cell sorting (FACS), using anti-
CD34 antibody (Caltag Laboratories, Burlingame, CA).
The mononuclear cells without CD34+, were plated onto
Iscove's Dulbeccos (IMDM) (Sigma, St Louis, MO, USA)
supplemented with 10% fetal bovine serum and 10%
horse serum. Supernatant with non-adherent cells was
removed weekly and replaced with fresh medium. When
the monolayer was established (90% confluence) cells
were trypsinized and plated under the same conditions.
After three re-platings, a homogeneous cell population
was obtained and the stromal cells were evaluated by
FACS for the absence of CD34, CD45 and CD68 antigens.
RNA extraction
Total RNA was extracted with RNAspin Mini RNA Isola-
tion Kit (GE Healthcare, Freiburg, Germany). The integ-
rity of RNA was evaluated using Agilent 2100
Electrophoresis Bioanalyzer (Agilent Technologies, Santa
Clara, CA).
Microarray experiments and data analysis
Gene expression measurements were performed using 44
k intron-exon oligoarrays that were custom-designed by
the group of Verjovski-Almeida and collaborators [25]
following Agilent Technologies probe specifications [37]
and were printed by Agilent. The array comprises 60-mer
oligonucleotide probes for 24,448 long (>500 nt) ncRNAs
mapping to 6,282 unique gene loci, with genomic coordi-
nates of the Human Genome May 2004 Assembly (hg17).
Non-coding RNAs probed on the array are transcribed
from either intronic regions in both the sense or the anti-
sense strands with respect to a protein-coding gene [25]
or from 1,124 intergenic regions [38]. The array also com-
prises 13,220 probes for the respective protein-coding
genes [25]. Gene locus name annotation for intronic
ncRNA is that of the protein-coding gene of the same
locus; intergenic ncRNA is annotated with the name of
the nearest protein-coding gene in that chromosome. All
annotations were updated as of December 2009. The
array design is deposited in the GEO platform under
accession number GPL9193.
For each individual sample, 150 ng total RNA was
amplified and labeled with Cy3 or Cy5 using the Agilent
Low RNA Input Fluorescent Linear Amplification Kit
PLUS, two-Color (Agilent Technologies) according to the
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manufacturer's recommendations. Labeled cRNA was
hybridized using Gene Expression Hybridization Kit
(Agilent).
Slides were washed and processed according to the Agi-
lent Two-Color Microarray-Based Gene Expression
Analysis protocol (Version 5.5) and scanned on a
GenePix 4000 B scanner (Molecular Devices, Sunnyvale,
CA, USA). Fluorescence intensities were extracted using
Feature Extraction (FE) software (version 9.0; Agilent). A
gene was considered expressed if probe intensity was sig-
nificantly (p > 0.05) higher than the local background
intensity, as calculated by the FE software. The software
then applied local background subtraction and corrected
unequal dye incorporation using the default LOWESS
(locally weighted linear regression) method. We have
included into further statistical analyses only those genes
that were detected as expressed in all samples.
Data were normalized among the samples by quantile
[39] using Spotfire DecisionSite® for Microarray Analysis
(TIBCO Software Inc, Somerville, MA, USA). Genes dif-
ferentially expressed between MDS-RARS and healthy
individuals were identified with the Significance Analysis
of Microarray (SAM) statistical approach [40] followed
by a patient leave-one-out cross validation [41], which
consisted in removing one sample and determining a new
set of significantly altered genes using the remaining sam-
ples. This procedure was repeated for each sample, com-
puting the statistical significance of each gene in the
various leave-one-out datasets. For both CD34+ and
stromal cell samples we used the following parameters:
two-class unpaired responses, t-statistic, 500 permuta-
tions. We considered as significantly altered those genes
that showed a minimum fold change of 1.7 and maximum
false discovery rate (FDR) of 1% for CD34+ or 5% for
stromal cells among all leave-one-out datasets. Less strin-
gent parameters (5% FDR for CD34+ or 15% for stromal
cells) were used for generating a list of altered genes that
was uploaded to Ingenuity Pathways Analysis (IPA) soft-
ware (Ingenuity® Systems, http://www.ingenuity.com) for
identification of relevant altered gene networks. The soft-
ware assigns statistical scores, taking into account the
user's set of significant genes, network size, and the total
number of molecules in Ingenuity Knowledge Base. The
network score is the negative logarithm of p-value, which
reflects the probability of finding the focus molecules in a
given network by random chance. The identified network
is then presented as a graph, indicating the molecular
relationships between gene products. The raw data has
been deposited in Gene Expression Omnibus (GEO)
http://www.ncbi.nlm.nih.gov/geo/ database under acces-
sion number GSE18911.
Gene Ontology Annotation (GOA) database http://
www.ebi.ac.uk/GOA/ was used for annotating the biolog-
ical processes of proteins encoded by transcripts that
were statistically significantly altered and showed at least
1.7-fold change in expression levels. Intronic non-coding
RNA transcripts were annotated according to the corre-
sponding protein-coding genes transcribed from the
same loci. Functional descriptions of the genes were
obtained from the Online Mendelian Inheritance in Man
(OMIM) database of the National Center for Biotechnol-
ogy Information (NCBI) http://www.ncbi.nlm.nih.gov/.
Quantitative real-time RT-PCR
Real-time RT-PCR was performed to confirm expression
levels of expression data for selected transcripts. Reverse
transcription was performed using Superscript™III
Reverse Transcriptase (Invitrogen Life Technologies).
Primers (Table 2) were designed using PRIMER3 soft-
ware (version 0.4.0) http://frodo.wi.mit.edu/primer3/
with published sequence data from the NCBI database.
For real-time PCR analysis, Power SYBR® Green PCR
Table 1: Characteristics of MDS-RARS patients at the time of BM collection.
Patients (n) Gene expression
 analyses for
 CD34+ cells
Gene 
expression 
analyses 
for stromal 
cells
Age (years) Gender Hb (g/dL) ANC
(×103/uL)
Platelet
count
(×103/uL)
BM blasts 
(%)
RS (%)
1 Array None 72 F 7.2 0.95 75 2 30
2 Array, qPCR None 78 M 8.3 1.23 136 0 58
3 Array, qPCR qPCR 62 M 12.4 0.99 110 2 16
4 Array, qPCR Array, qPCR 70 M 10.2 5.34 322 0 38
5 qPCR Array, qPCR 69 F 6.7 0.51 72 0 22
6 qPCR Array, qPCR 56 M 8.4 2.81 754 0 91
7 None qPCR 75 M 6.3 0.75 216 0 27
Hb indicates hemoglobin; ANC, absolute neutrophil account; BM, bone marrow; and RS, ring sideroblasts
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Master Mix (Applied Biosystems) was used, according to
the manufacturer's instructions, and the reactions were
run in a 7500 Real-Time PCR Systems (Applied Biosys-
tems) for 40 cycles. Each sample measurement was per-
formed in triplicate and a negative control, "No Template
Control", was included for each primer pair. Expression of
transcripts was normalized to the HPRT endogenous
gene, and the relative expression was calculated as 2-ΔΔCT,
where ΔΔCT is the CT value difference for each patient
normalized by the average CT difference of samples from
healthy subjects (ΔΔCT method) [42].
Results
Protein-coding and non-coding transcripts expression 
profiles in CD34+ cells
CD34+ cells obtained from 4 patients with MDS-RARS
(nos. 1-4; Table 1) were compared with CD34+ cells of
healthy individuals using custom-designed combined
intron-exon expression oligoarrays [25]. The oligoarray
includes probes for protein-coding genes and for both
sense and antisense strands of ncRNAs, as described in
the Methods. In order to reduce the effect of individual
variability, thus promoting the identification of a robust
gene expression signature of MDS-RARS, Significance
Analysis of Microarrays (SAM) [40] was combined with a
patient leave-one-out cross validation [41]. A total of 216
significantly (q-value ≤ 0.01) differentially expressed tran-
scripts between MDS-RARS patients and healthy indi-
viduals were identified (Figure 1), being 129 down-
regulated and 87 up-regulated in MDS-RARS (Additional
file 1). Interestingly, 65 differentially expressed tran-
scripts were ncRNAs, 32 down-regulated and 33 up-reg-
ulated (Table 3).
Differentially expressed protein-coding genes were
related to cell adhesion, apoptosis, ion transport and reg-
ulation of transcription (Table 4). Six protein-coding
genes, namely ABCB7, EBF1, IFI30, IL10RA, NR4A2 and
VEGF, have been previously shown in the literature as
differentially expressed in MDS-RARS [7,43-45]. In addi-
tion, we identified a number of protein-coding tran-
scripts not previously described as altered in MDS-
RARS.
Ingenuity Pathways Analysis (IPA) was used for identi-
fying enriched gene networks and functions among the
differentially transcribed protein-coding genes. We iden-
tified 11 relevant networks that were significantly
Table 2: Sequences of primers for real-time RT-PCR assays.
sense antisense
Genes selected for validation in CD34+ cells
MY5OC 5'CGTGGCAGAAGAGGCATACA3' 5'AGCGAGCCGACACTGTCTTT3'
GCDH_ncRNA 5'aaggagctttgggtttttgt3' 5'cgccttagtgacagtctccag3'
HCK 5'GAGTTCATGGCCAAAGGAAG3' 5'GGAGGTCTCGGTGGATGTAG3'
PPIF_ncRNA 5'atcgagctttgggggtagat3' 5'agcaacagtgtagcgcaatg3'
NR4A2 5'ACTCCAACCCGGCTATGAC3' 5'CATGGAGCCAGTCAGGAGAT3'
NR4A2_ncRNA 5'cttccgggtgtctgagaaag3' 5'tttgcatgtgctaggagctg3'
NR4A3 5'TCCAGATACTGTCCCACTGACC3' 5'TCTGGATACATCAATGGAGGCT3'
NR4A3_ncRNA 5'ccgttaagcacctggttttc3' 5'aggcgctgagaattattgga3'
Genes selected for validation in stromal cells
SPINT2 5'TCTGTTTCTCTGGGAGGTAGGA3' 5'CGATCAGCGAGGAAACAACT3'
HLA-E 5'ATCGTGGGCATCATTGCT3' 5'GAGTAGCTCCCTCCTTTTCCA3'
SEMA3A 5'AGGGACCGAAAACAACGTC3' 5'CGTGGGTCCTCCTGTTTCTA3'
TBCD_ncRNA 5'TCTTGCCTGGTGAGTGTGAG3' 5'AAGGTGTTGGAAGGGAGGAG3'
SOLH_ncRNA 5'AGTCTCCAGAGTGGCATGTG3' 5'AAAGGTAGGCAGGGGAGGTA3'
Endogenous gene
HPRT 5'TCCAGCAGGTCAGCAAAGAA3' 5'GAACGTCTTGCTCGAGATGT3'
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Table 3: ncRNAs with significantly altered CD34+ expression in MDS-RARS patients in relation to healthy individuals.
Gene Locus
name1
Locus ID ncRNA Probe Coordinates Probe Strand Type Orientation relative to protein coding gene q value2 Fold Change
Down-regulation in MDS-RARS
NEIL1 79661 chr15:73434282-73434341 + Intronic Sense 0.000 -4.45
BLNK 29760 chr10:97961400-97961459 - Intronic Sense 0.000 -3.59
KLHL5 51088 chr4:38941503-38941562 + Intronic Sense 0.004 -2.92
LEF1 51176 chr4:109454925-109454984 + Intergenic Antisense 0.001 -2.80
GABPB1 2553 chr15:48447272-48447331 + Intergenic Antisense 0.000 -2.55
TLE1 7088 chr9:81478431-81478490 - Intronic Sense 0.000 -2.30
TNFAIP3 7128 chr6:138230463-138230522 - Intronic Antisense 0.000 -2.21
IGSF10 285313 chr3:152637104-152637163 + Intergenic Sense 0.000 -2.19
CPSF6 11052 chr12:67954327-67954386 - Intronic Antisense 0.000 -2.16
MORN1 79906 chr1:2326963-2327014 - Intronic Sense 0.003 -2.15
ASAP2 8853 chr2:9299234-9299293 + Intronic Sense 0.003 -2.14
ST7OT1 93653 chr7:116186492-116186551 - Intergenic Sense 0.004 -2.13
TLE1 7088 chrX:64411696-64411755 + Intronic Sense 0.000 -2.12
NASP 4678 chr1:45744001-45744060 + Intronic Sense 0.001 -2.10
TLE1 7088 chr9:81478491-81478550 - Intronic Sense 0.000 -2.10
PIAS2 9063 chr18:42643244-42643303 - Intergenic Sense 0.000 -2.05
NUP153 9972 chr6:17815444-17815503 + Intergenic Sense 0.001 -2.04
ZNF76 7629 chr6:35364312-35364371 + Intronic Sense 0.002 -2.02
ERO1LB 56605 chr1:232705155-232705214 - Intronic Antisense 0.000 -1.98
CPSF6 11052 chr12:67954327-67954386 - Intronic Antisense 0.000 -1.97
ASXL1 171023 chr20:30410722-30410781 + Intronic Sense 0.001 -1.94
C5orf13 9315 chr5:111094583-111094642 + Intronic Antisense 0.000 -1.86
PRG4 10216 chr1:183013558-183013617 - Intronic Antisense 0.000 -1.86
GABPB1 2553 chr15:48448783-48448842 + Intergenic Antisense 0.003 -1.85
AFF1 4299 chr4:88268668-88268724 + Intronic Sense 0.000 -1.83
PAG1 55824 chr8:82068816-82068875 - Intronic Sense 0.001 -1.83
LOC441242 441242 chr7:63977853-63977912 - Intergenic Sense 0.003 -1.82
AASS 10157 chr7:121332812-121332871 + Intronic Antisense 0.001 -1.79
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GCDH 2639 chr19:12871038-12871097 - Intronic Antisense 0.000 -1.79
SNORA71B 26776 chr20:36482692-36482751 - Intergenic Sense 0.001 -1.77
AFF3 3899 chr2:99698165-99698216 - Intronic Sense 0.004 -1.76
RBM4B 83759 chr11:66192338-66192397 + Intronic Sense 0.001 -1.73
Up-regulation in MDS-RARS
NR4A3 8013 chr9:99668743-99668802 + Intronic Sense 0.001 5.52
NR4A2 4929 chr2:157011025-157011084 - Intronic Sense 0.002 4.49
CCDC146 57639 chr7:76467266-76467325 - Intronic Antisense 0.003 4.03
MARCH1. 55016 chr4:164805948-164806007 - Intergenic Sense 0.002 3.77
THBS1 7057 chr15:37668391-37668450 + Intronic Sense 0.001 2.77
FN1 2335 chr2:216086310-216086369 + Intronic Antisense 0.000 2.71
RALGPS1 9649 chr9:126945696-126945747 + Intronic Antisense 0.000 2.70
SERPINA1 5265 chr14:93919199-93919258 + Intronic Antisense 0.001 2.51
EHBP1L1 254102 chr11:65104384-65104443 - Intronic Antisense 0.001 2.38
PPIF 10105 chr10:80781110-80781169 - Intronic Antisense 0.003 2.36
ANK3 288 chr10:61625808-61625867 - Intronic Sense 0.004 2.30
PPIF 10105 chr10:80781110-80781169 + Intronic Sense 0.001 2.29
ZSCAN10 84891 chr16:3082319-3082378 - Intronic Sense 0.004 2.24
B3GNT5 84002 chr3:184455731-184455790 + Intronic Sense 0.001 2.21
CYBASC3 220002 chr11:60883741-60883792 - Intronic Sense 0.002 2.21
NR4A2 4929 chr2:157012210-157012269 + Intronic Antisense 0.004 2.15
IFI30 10437 chr19:18147121-18147180 - Intronic Antisense 0.004 2.12
DHX38 9785 chr16:70696571-70696630 + Intronic Sense 0.000 2.11
FAM50A 9130 chrX:153324988-153325047 + Intronic Antisense 0.002 2.05
SESTD1 91404 chr2:179802621-179802672 + Intronic Antisense 0.000 1.91
CC2D1A 54862 chr19:13891701-13891760 - Intronic Antisense 0.002 1.88
SNX20 124460 chr16:49264159-49264218 - Intronic Sense 0.000 1.88
ICA1 3382 chr7:7932382-7932433 - Intronic Sense 0.000 1.86
NCOA3 8202 chr20:45714557-45714616 - Intronic Antisense 0.003 1.86
FRAS1 80144 chr4:79383367-79383426 + Intronic Sense 0.004 1.85
TMBIM6 7009 chr12:48437217-48437268 + Intronic Sense 0.001 1.85
CD44 960 chr11:35184235-35184294 - Intronic Antisense 0.000 1.83
PPP1R15A 23645 chr19:54068439-54068498 - Intronic Antisense 0.002 1.82
Table 3: ncRNAs with significantly altered CD34+ expression in MDS-RARS patients in relation to healthy individuals. (Continued)
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PKM2 5315 chr15:70288031-70288090 + Intronic Antisense 0.000 1.81
RP5-1022P6.2 56261 chr20:5491968-5492027 - Intronic Sense 0.002 1.81
DAGLBETA 221955 chr7:6274325-6274384 + Intronic Antisense 0.003 1.78
RAD51L1 5890 chr14:67951712-67951763 - Intronic Antisense 0.001 1.77
S100A4 6275 chr1:150330268-150330327 + Intronic Antisense 0.001 1.71
1Gene locus name for intronic ncRNA is that of the protein-coding gene of the same locus; intergenic ncRNA is annotated with the name of the nearest protein-coding gene in that chromosome.
2Minimum significance among all patient Leave-one-out analyses
Table 3: ncRNAs with significantly altered CD34+ expression in MDS-RARS patients in relation to healthy individuals. (Continued)
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enriched (p-value < 0.001) with genes belonging to the
MDS-RARS gene expression signature in CD34+ cells
(Additional file 2). Figure 2 shows a gene network
involved in hematological system development and func-
tion, humoral immune response and tissue morphology.
Eight transcripts were chosen to validate microarray
data by real-time RT-PCR. RNA extracted from CD34+
cells from 5 MDS-RARS patients (nos. 2-6; Table 1) was
calculated as fold change compared with healthy con-
trols. All transcripts were confirmed by real-time RT-
PCR (Figure 3).
Protein-coding and ncRNA transcript expression profiles in 
stromal cells
Stromal cells obtained from three MDS-RARS patients
(nos. 4-6; Table 1) were compared with stromal cells of
healthy individuals using the same custom-designed
combined intron-exon expression oligoarrays and signifi-
cance analysis. SAM combined with patient leave-one-
out cross validation identified 12 significantly (q-value ≤
0.05) differentially expressed genes (10 up-regulated and
2 down-regulated in stromal cells of MDS-RARS
patients) (Figure 4; Additional file 3), of which 3 were
ncRNAs (up-regulated in MDS-RARS patients) (Table 5).
The low number of differentially expressed genes was
mostly due to the high homogeneity of stromal cells from
patients and donors (correlation coefficient between all
donor and patient stromal samples = 0.93, contrasted to
0.9 of CD34+ cells, p = 10-5). The signature expression
profile of protein-coding transcripts in MDS-RARS
stromal cells revealed genes related to several biological
processes, such as cell motility, DNA replication, protein
amino acid phosphorylation and protein transport (Table
4).
Ingenuity Pathways Analysis (IPA) of stromal cell genes
statistically differentially expressed between MDS-RARS
patients and healthy individuals (fold change ≥ 1.7; q-
value ≤ 0.15 in all patient leave-one-out cross-validation
analyses) identified two significantly enriched gene net-
works (p-value < 0.001) (Additional file 2). The most sig-
nificantly enriched gene network involves genes related
to cell morphology, cellular compromise, and neurologi-
cal disease (Figure 5).
Four transcripts were chosen to validate microarray
data by real-time RT-PCR. RNA extracted from stromal
cells from 5 MDS-RARS patients (nos. 3-7; Table 1) was
used for validation studies; all transcripts were confirmed
by real-time RT-PCR (Figure 6).
Discussion
In this study, we used the 44 k intron-exon oligoarray and
stringent statistical criteria to determine the protein-cod-
ing and intronic non-coding transcript expression pro-
files in CD34+ and stromal cells of MDS-RARS patients
and healthy individuals. We herein validated the expres-
sion of a set of selected transcripts by real time RT-PCR
in five MDS-RARS patients, however future confirmation
in a larger group of MDS-RARS cases is warranted. Path-
way analyses of differential protein-coding transcripts
pointed to new genetic networks that are altered in both
Figure 1 Differentially expressed transcripts in CD34+ cells of 
MDS-RARS patients and healthy individuals. The panel shows the 
expression matrix of 216 significantly differentially expressed genes in 
CD34+ cells of MDS-RARS patients compared to healthy individuals 
(SAM FDR <1% and fold change ≥1.7). Each row represents a single 
gene probe (151 protein-coding and 65 ncRNAs) and each column 
represents a separate CD34+ donor sample. Donor samples were clus-
tered according to the correlation of expression profiles using the Un-
weighted Pair-Group Method, which resulted in two homogenous 
groups: MDS-RARS patients (4 columns at left) and healthy individuals 
(4 columns at right). Expression level of each gene is represented by 
the number of standard deviations above (red) or below (green) the 
average value for that gene across all samples. In MDS-RARS patients, 
a total of 87 genes were up-regulated and 129 down-regulated.
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CD34+ and stromal cells of MDS-RARS patients (Addi-
tional file 2).
MDS are characterized by hematopoietic insufficiency
associated with cytopenia, leading to severe morbidity in
addition to increased risk of leukemia transformation
[46]. The exact stage of CD34+ progenitor cells involved
in the process of MDS and transformation to AML are
still in debate. Bone marrow microenvironment contrib-
utes to regulate self-renewal, commitment, differentia-
tion, proliferation and the dynamics of apoptosis of
hematopoietic progenitors [47], and CD34+ progenitor
cells are known to be severely impacted in MDS by the
composition of micro environmental stimuli [48]. Detec-
tion of differentially expressed transcripts in MDS-RARS
stromal cells suggests that these transcripts could con-
tribute to maintain CD34+ cells.
Pathways analysis of the set of protein-coding tran-
scripts altered in CD34+ cells of MDS-RARS patients
revealed an important gene network related to hemato-
logical disease, including BLNK, CD19, CD72, CD81,
EBF1, F5, FLT3, LY96, MPDZ and THBS1. Down-regula-
tion in MDS-RARS of genes related to the B cell receptor
Table 4: Biological processes of genes differentially expressed in CD34+ and stromal cells from MDS-RARS patients.
Genes Differentially Expressed
Biological Process1 in CD34+ Cells in Stromal Cells
apoptosis ↓CYFIP2, ↓MGC29506, ↑PHLDA2, ↑SGK1, ↓SOCS2, ↓TNFRSF21, ↑TNFRSF1B, 
↓UNC13B
___________
blood coagulation ↓SEC63, ↑SERPINA1 ___________
cell adhesion ↓AEBP1, ↓COL5A1, ↓CYFIP2, ↑ITGAX, ↓JAM2, ↓LAMB2, ↓LAMC1, ↓PCDH9, ↓PDZD2, 
↓ROBO1, ↑VCAN
↑RGMB
cell cycle ↓E2F7, ↓NASP, ↓UHRF1 ____________
cell differentiation ↓NAV1, ↓ROBO1 ↑SEMA3A
cell motility ____________ ↓SPINT2
cell proliferation ↓CD81, ↓DLG3, ↓FLT3, ↑LRP1, ↓NASP, ↓NPY, ↑S100A11, ↓UHRF1, ↑VEGFA ____________
DNA replication ____________ ↑KRT7
exocytosis ↓NKD2, ↓RIMS3, ↓UNC13B ____________
immune response ↓CD19, ↑CTSS, ↓ERAP1, ↑OAS1, ↓PXDN ↓HLA-E
inflammatory response transport ↑AOAH, ↓C5, ↓BLNK, ↑LY96 ____________
↓ABCB7, ↓COL5A1, ↑HVCN1, ↓KCNE1L, ↓KCNMB3, ↓KCNMB4, ↓NKD2, ↓NPY, 
↑SGK1, ↑SGSH, ↑SLC8A1, ↑SLC11A2, ↓SLC12A2, ↑SLC37A2, ↓SLC39A8, ↑SLC43A2
↑SCFD2, ↓GRIA3
oxidation reduction ↓AASS, ↑CYB5R1, ↑IFI30, ↓PTGR1, ↓PXDN ↑LEPREL1
protein amino acid phosphorylation ↓FLT3, ↑HCK, ↑SGK1 ↓TNIK
regulation of transcription ↓ECHDC2, ↓AEBP1, ↓AFF3, ↓BACH2, ↓CEP290, ↓E2F7, ↓EBF1, ↓ELP2, ↑ETV3, ↑JAZF1, 
↓LOC400713, ↑NCOA4, ↑NR4A2, ↑NR4A3, ↓POU2AF1, ↑RXRA, ↓TLE1, ↓UHRF1, 
↓ZNF711, ↓ZNF91
___________
rRNA processing ____________ ___________
signal transduction ↓ANK3, ↑ARHGEF10L, ↓C13orf18,↑NR4A2, ↓PSD3, ↑S100A11, ↓TLE1, ↓TNFRSF21 ____________
others ↑AADACL1, ↓AADAT, ↑ACPP, ↓ACSM3, ↑ADCY7, ↓AHI1, ↓ALS2CR4, ↓AUTS2, 
↓C16orf67, ↓C1orf21, ↓C9orf58, ↑CALML4, ↓CCDC136, ↓CLIP3, ↑COLT1, ↑CTSH, 
↓CYYR1, ↑DDX3X, ↑DDX3Y, ↓DPY19L2, ↓EBF1, ↓EHBP1L1, ↓FAAH, ↑FGD6, 
↑FGFR1OP2, ↓HHAT, ↓HS3ST1, ↑IL10RA, ↑JHDM1D, ↓LAYN, ↑LFNG, ↓LRIG1, 
↓MMP11, ↓MPDZ, ↓MYO1D, ↓MYO5C, ↓NEIL1, ↓PLS3, ↓SH2D4B, ↓SNORA71B, 
↓SPATS2, ↓ST7OT1, ↓TMEM217, ↓TOP2B, ↑TSPAN14, ↓TSPYL5, ↓UQCC, ↑WIPI1
___________
1The biological processes categories were obtained from the GOA database. Genes (↑) up-regulated or (↓) down-regulated in MDS-RARS patients 
with respect to healthy individuals.
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signaling pathway were found in our results (BLNK,
CD19 and CD72), and the low expression of several genes
involved in B lymphocyte development, corroborate the
hypothesis that early MDS can be defined by a B-cell pro-
genitor defect [49].
The abnormal expression of genes encoding mitochon-
drial proteins involved in iron metabolism has been char-
acterized in MDS-RARS [7,50]. The present study found
3 different ncRNA transcripts with altered expression in
the CD34+ cells of MDS-RARS patients, from gene loci of
mitochondrial proteins (AASS, GCDH and PPIF) and 6
modulated mitochondrial protein-coding transcripts. In
addition, corroborating our findings, the down regulation
of iron transporter ABCB7 has been described in CD34+
cells of patients MDS-RARS, indicating that low ABCB7
levels would contribute to abnormal mitochondrial iron
Figure 2 Significantly enriched gene network of protein-coding genes with altered expression in CD34+ cells. Ingenuity Pathways Analysis 
identified that the top most significantly enriched (p < 0.001) functions of genes in this network were related to hematological system development 
and function, humoral immune response and tissue morphology. Gene color intensity indicates the degree of up-regulation (red) or of down-regu-
lation (green) in CD34+ cells of MDS-RARS patients in comparison to healthy individuals. Genes in gray were not identified as differentially expressed 
in our experiment and white genes were either not detected as expressed in these cells or not present in our oligoarray platform. Solid lines indicate 
direct interaction and dashed lines indirect interactions.
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homeostasis [43]. Furthermore, genes related to heme
biosynthesis pathway and transferrin trafficking (PXDN
and MYO5C, respectively), were down regulated in MDS-
RARS CD34+ cells. These differentially expressed genes
could be related to the iron accumulation observed in
mitochondria of RARS patients.
One of the mechanisms that contribute to hypercellular
marrow and peripheral blood cytopenia of patients with
early stage MDS is the significant increase in apoptosis of
hematopoietic cells [51]. The higher expression of Fas-
FasL system found in MDS plays a role in inducing MDS
bone marrow apoptosis and works in both an autocrine
(hematopoietic cell-hematopoietic cell interaction) or
paracrine (hematopoietic cell-stromal cell interaction)
pattern [52]. The protein encoded by SEMA3A (Class 3
semaphorins), a secreted member of the semaphorin
family involved in axonal guidance, organogenesis, angio-
genesis, and highly expressed in several tumor cells
[53,54], has recently been demonstrated to be an impor-
tant determinant of leukemic cells sensitivity to Fas-
mediated apoptosis signal [55]. Furthermore, Sema3A
has already been described to act through different sig-
naling pathways to control neural progenitor cell repul-
sion activating Erk1/2 or apoptosis process involving
p38MAPK [56]. Surprisingly, SEMA3A is present in both
affected networks of MDS-RARS stromal cells (see Addi-
tional file 2), suggesting participation of this gene in
diverse abnormalities implicated in the modification of
hematopoietic cells development and apoptosis in MDS
[12,13].
The non-coding expression profiles of CD34+ and
stromal cells of MDS-RARS were clearly distinct from
Figure 3 Validation of gene expression data of CD34+ cells by 
real-time RT-PCR. Comparison of gene expression levels by real-time 
RT-PCR (black bars) and microarray experiments (gray bars) for eight 
select genes (names indicated at bottom) in CD34+ cells of MDS-RARS 
patients and healthy individuals. Positive and negative fold change val-
ues indicate the up- or down-regulation of expression in MDS-RARS 
patients in relation to the expression in healthy individuals, respective-
ly.
Table 5: ncRNAs differentially expressed in stromal cells of MDS-RARS patients in comparison to healthy individuals.
Gene Locus
Name1
Locus ID ncRNA Probe 
Coordinates
Probe 
Strand
Type Orientation in relation 
to protein coding gene
q value2 Fold Change
Up-regulation in MDS-RARS
SOLH 6650 chr16:529804-529859 + Intronic Sense 0.000 4.40
CROCC 9696 chr1:16968607-16968658 + Intergenic Sense 0.038 2.40
TBCD 6904 chr17:78399392-78399451 + Intronic Sense 0.042 2.00
1 Gene locus name for intronic ncRNA is that of the protein-coding gene of the same locus; intergenic ncRNA is annotated with the name of the 
nearest protein-coding gene in that chromosome.
2 Minimum significance among all patient Leave-one-out analyses
Figure 4 Differentially expressed transcripts in stromal cells of 
MDS-RARS patients and healthy individuals. The panel shows the 
expression matrix of 12 significantly differentially expressed genes in 
stromal cells of MDS-RARS patients compared to healthy individuals 
(SAM FDR <5% and fold change ≥1.7). Each row represents a single 
gene (9 protein-coding genes with names in black, and 3 ncRNAs in 
blue) and each column represents a separate stromal donor sample. 
Donor samples were clustered according to the correlation of expres-
sion profiles using the Unweighted Pair-Group Method, which resulted 
in two homogenous groups: MDS-RARS patients (3 columns at right) 
and healthy individuals (4 columns at left). Expression level of each 
gene is represented by the number of standard deviations above (red) 
or below (green) the average value for that gene across all samples. In 
MD-RARS patients, a total of 10 genes were up-regulated and 2 down-
regulated.
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those obtained from CD34+ and stromal cells of healthy
controls, representing 30% and 25% of the total amount
of differentially expressed genes in CD34+ and stromal
cells of MDS-RARS patients, respectively. Currently, evi-
dence of the biological roles played by ncRNA have
increased, especially those transcribed from partially
conserved introns of protein-coding genes [57]. Recently,
eosinophil granule ontogeny (EGO) has been shown to
involve an ncRNA expressed during IL-5 stimulation,
whose function is to regulate MBP granule protein and
EDN mRNA levels [58].
Interestingly, our results showed 13 differentially
expressed ncRNA transcripts in CD34+ cells of MDS-
RARS patients for which there was a simultaneous
change in expression of the protein-coding gene in the
corresponding locus: for 7 of them both the ncRNA and
the protein-coding gene were simultaneously down-regu-
lated in MDS-RARS, 5 were up-regulated, and in one
gene locus the TIN ncRNA was up-regulated whereas the
protein-coding gene was down-regulated. Expression of
both, protein-coding and non-coding pairs in the same
locus, suggest that these intronic ncRNAs may act upon
cis-regulatory factors, modulating the stability and/or
Figure 5 Most enriched gene network of protein-coding genes with altered expression in stromal cells. Ingenuity Pathways Analysis identified 
that the top most significantly enriched (p <0.001) functions of genes in this network were related to cell morphology, cellular compromise and neu-
rological disease. Gene color intensity indicates the degree of up-regulation (red) or of down-regulation (green) in stromal cells of MDS-RARS patients 
in comparison to healthy individuals. Genes in gray were not identified as differentially expressed in our experiment and white genes were either not 
detected as expressed in these cells or not present in our oligoarray platform. Solid lines indicate direct interaction and dashed lines indirect interac-
tions.
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processing of the corresponding protein-coding tran-
script, or even directly affecting the levels and/or the
splicing of protein-coding isoforms [27,59]. We found 2
altered genes of the nuclear receptor subfamily 4, group A
(NR4A2 e NR4A3), known to be involved in T-cell apop-
tosis, brain development, and vascular disease [60], and
both showed a simultaneous up-regulation of the pro-
tein-coding and the ncRNA from the same locus in MDS-
RARS, suggesting that these ncRNAs could be involved in
the control of protein coding expression of this gene fam-
ily in MDS-RARS patients.
Conclusion
The presence of intronic ncRNA transcripts differentially
expressed in CD34+ and stromal cells may shed light
upon the not yet fully understood molecular mechanisms
involved in the heterogeneity of myelodysplastic syn-
dromes and suggest that ncRNAs may play a role during
disease development. Characterization of those ncRNA
transcripts would contribute to a better understanding of
MDS-RARS, or even towards the development of bio-
markers and therapeutic targets.
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